Measurement of erythrocyte methotrexate polyglutamate levels: Ready for clinical use in rheumatoid arthritis?

Maria I. Danila; Laura B. Hughes; Elizabeth E. Brown; Sarah L. Morgan; Joseph E. Baggott; Donna K. Arnett; S. Louis Bridges

doi:10.1007/s11926-010-0120-3

Measurement of erythrocyte methotrexate polyglutamate levels: Ready for clinical use in rheumatoid arthritis?

Maria I. Danila, Laura B. Hughes, Elizabeth E. Brown, Sarah L. Morgan, Joseph E. Baggott, Donna K. Arnett, S. Louis Bridges

Research output: Contribution to journal › Review article › peer-review

27 Scopus citations

Abstract

Methotrexate (MTX) is one of the most commonly prescribed and most effective drugs for the treatment of rheumatoid arthritis (RA). Given the partial response of many patients and the side effect profile of the drug, there is considerable interest in identifying biomarkers to guide MTX therapy in RA. Upon entering cells, MTX is polyglutamated. Measuring MTX polyglutamate (MTX PG) levels in circulating red blood cells has been proposed as an objective measure to help optimize MTX therapy in RA. Data are conflicting with regard to the clinical utility of MTX PG measurements as a predictor of the efficacy or toxicity of lowdose MTX effects in RA. Should large, randomized clinical trials of this assay show consistent, reproducible, long-term correlations between MTX PG levels and efficacy or toxicity, this test could become a prominent tool for clinicians to optimize the use of MTX in treating RA.

Original language	English
Pages (from-to)	342-347
Number of pages	6
Journal	Current Rheumatology Reports
Volume	12
Issue number	5
DOIs	https://doi.org/10.1007/s11926-010-0120-3
State	Published - Oct 2010

Bibliographical note

Funding Information:
Acknowledgments This work was supported by National Institutes of Health grants 2P60 AR048095-06 (University of Alabama at Birmingham Multidisciplinary Clinical Research Center, R. P. Kimberly, principal investigator) and the MCRC Project 1 (D. K. Arnett, principal investigator).

Funding

Acknowledgments This work was supported by National Institutes of Health grants 2P60 AR048095-06 (University of Alabama at Birmingham Multidisciplinary Clinical Research Center, R. P. Kimberly, principal investigator) and the MCRC Project 1 (D. K. Arnett, principal investigator).

Funders	Funder number
University of Alabama at Birmingham Multidisciplinary Clinical Research Center
National Institutes of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases	P60AR048095

Keywords

Methotrexate
Polyglutamates
Rheumatoid arthritis

ASJC Scopus subject areas

Rheumatology

Access to Document

10.1007/s11926-010-0120-3

Cite this

@article{e3ebe8b55d754a0581ede4c8d51c538f,

title = "Measurement of erythrocyte methotrexate polyglutamate levels: Ready for clinical use in rheumatoid arthritis?",

abstract = "Methotrexate (MTX) is one of the most commonly prescribed and most effective drugs for the treatment of rheumatoid arthritis (RA). Given the partial response of many patients and the side effect profile of the drug, there is considerable interest in identifying biomarkers to guide MTX therapy in RA. Upon entering cells, MTX is polyglutamated. Measuring MTX polyglutamate (MTX PG) levels in circulating red blood cells has been proposed as an objective measure to help optimize MTX therapy in RA. Data are conflicting with regard to the clinical utility of MTX PG measurements as a predictor of the efficacy or toxicity of lowdose MTX effects in RA. Should large, randomized clinical trials of this assay show consistent, reproducible, long-term correlations between MTX PG levels and efficacy or toxicity, this test could become a prominent tool for clinicians to optimize the use of MTX in treating RA.",

keywords = "Methotrexate, Polyglutamates, Rheumatoid arthritis",

author = "Danila, {Maria I.} and Hughes, {Laura B.} and Brown, {Elizabeth E.} and Morgan, {Sarah L.} and Baggott, {Joseph E.} and Arnett, {Donna K.} and Bridges, {S. Louis}",

note = "Funding Information: Acknowledgments This work was supported by National Institutes of Health grants 2P60 AR048095-06 (University of Alabama at Birmingham Multidisciplinary Clinical Research Center, R. P. Kimberly, principal investigator) and the MCRC Project 1 (D. K. Arnett, principal investigator).",

year = "2010",

month = oct,

doi = "10.1007/s11926-010-0120-3",

language = "English",

volume = "12",

pages = "342--347",

number = "5",

}

TY - JOUR

T1 - Measurement of erythrocyte methotrexate polyglutamate levels

T2 - Ready for clinical use in rheumatoid arthritis?

AU - Danila, Maria I.

AU - Hughes, Laura B.

AU - Brown, Elizabeth E.

AU - Morgan, Sarah L.

AU - Baggott, Joseph E.

AU - Arnett, Donna K.

AU - Bridges, S. Louis

N1 - Funding Information: Acknowledgments This work was supported by National Institutes of Health grants 2P60 AR048095-06 (University of Alabama at Birmingham Multidisciplinary Clinical Research Center, R. P. Kimberly, principal investigator) and the MCRC Project 1 (D. K. Arnett, principal investigator).

PY - 2010/10

Y1 - 2010/10

N2 - Methotrexate (MTX) is one of the most commonly prescribed and most effective drugs for the treatment of rheumatoid arthritis (RA). Given the partial response of many patients and the side effect profile of the drug, there is considerable interest in identifying biomarkers to guide MTX therapy in RA. Upon entering cells, MTX is polyglutamated. Measuring MTX polyglutamate (MTX PG) levels in circulating red blood cells has been proposed as an objective measure to help optimize MTX therapy in RA. Data are conflicting with regard to the clinical utility of MTX PG measurements as a predictor of the efficacy or toxicity of lowdose MTX effects in RA. Should large, randomized clinical trials of this assay show consistent, reproducible, long-term correlations between MTX PG levels and efficacy or toxicity, this test could become a prominent tool for clinicians to optimize the use of MTX in treating RA.

AB - Methotrexate (MTX) is one of the most commonly prescribed and most effective drugs for the treatment of rheumatoid arthritis (RA). Given the partial response of many patients and the side effect profile of the drug, there is considerable interest in identifying biomarkers to guide MTX therapy in RA. Upon entering cells, MTX is polyglutamated. Measuring MTX polyglutamate (MTX PG) levels in circulating red blood cells has been proposed as an objective measure to help optimize MTX therapy in RA. Data are conflicting with regard to the clinical utility of MTX PG measurements as a predictor of the efficacy or toxicity of lowdose MTX effects in RA. Should large, randomized clinical trials of this assay show consistent, reproducible, long-term correlations between MTX PG levels and efficacy or toxicity, this test could become a prominent tool for clinicians to optimize the use of MTX in treating RA.

KW - Methotrexate

KW - Polyglutamates

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=78149471358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149471358&partnerID=8YFLogxK

U2 - 10.1007/s11926-010-0120-3

DO - 10.1007/s11926-010-0120-3

M3 - Review article

C2 - 20665136

AN - SCOPUS:78149471358

SN - 1523-3774

VL - 12

SP - 342

EP - 347

JO - Current Rheumatology Reports

JF - Current Rheumatology Reports

IS - 5

ER -

Measurement of erythrocyte methotrexate polyglutamate levels: Ready for clinical use in rheumatoid arthritis?

Abstract

Bibliographical note

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this